Bremelanotide is approved for use in premenopausal women diagnosed with acquired, generalized HSDD. It is not indicated for postmenopausal women, men, or individuals with other sexual dysfunctions. Patients considering this medication should undergo a comprehensive evaluation by a healthcare provider to confirm the diagnosis of HSDD.
